Last reviewed · How we verify
NCT04720352: PURSUIT
Prospective US Radiofrequency SUI Trial
NA trial testing Active treatment in Urinary Incontinence, Stress in 390 participants. Status unknown.
30 December 2022
Quick facts
| Lead sponsor | Viveve Inc. |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 390 |
| Start date | 11 January 2021 |
| Primary completion | 30 December 2022 |
| Estimated completion | 30 December 2022 |
| Sites | 29 locations across United States |
Drugs / interventions tested
- Active treatment — full drug profile →
- Sham
Conditions studied
- Urinary Incontinence, Stress — all drugs for Urinary Incontinence, Stress →
Sponsor
Viveve Inc.
Who can join
18 and older, female only, with Urinary Incontinence, Stress. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
PURSUIT: Prospective US Radiofrequency SUI Trial (VI-17-06) is a prospective, randomized, sham controlled, double blind study in premenopausal women with stress urinary incontinence. The study will be conducted in 390 subjects, randomized 2:1 with active or sham treatment. Study duration is 12 months post treatment. The primary objective is to evaluate the efficacy of the Viveve treatment, SUI protocol, in improving mild to moderate stress urinary incontinence (SUI), assessed using the 1-hour Pad Weight Test for up to 12 months post-treatment.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04720352
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Active treatment
Trials testing the same drug.
- NCT06776978 — Effectiveness of TDCS Over Broca's Area in Verb Naming: a Randomized, Double-Blind, Crossover Study · NA · completed
Other recruiting trials for Urinary Incontinence, Stress
Currently open trials in the same condition.
- NCT06933407 — Elastographic Assessment of Suburethral Tissue in Continent and Incontinent Women · recruiting
- NCT04114266 — Registry for Patients Undergoing AUS Surgery for Female SUI Due to ISD · active not recruiting
Other Viveve Inc. trials
Trials by the same sponsor.
- NCT04206085 — Comparison of the Viveve Treatment and Cryogen-Only Treatment Versus Sham Treatment for Stress Urinary Incontinence · NA · completed
- NCT03619174 — LIBERATE International · NA · completed
- NCT03479229 — Viveve Geneveve Treatment of the Vaginal Introitus to Evaluate Safety and Efficacy · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04720352 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Viveve Inc.
- Last refreshed: 26 July 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04720352.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing